

CI Global Health Sciences Corporate Class

SUMMARY OF INVESTMENT PORTFOLIO as at December 31, 2023

Category	% of Net Assets	Category	% of Net Assets	Top 25 Holdings	% of Net Assets
Country allocation		Sector allocation		Humana Inc.	9.8
U.S.A.	76.0	Health Care	94.5	UnitedHealth Group Inc.	9.1
U.K.	8.4	Exchange-Traded Fund(s)	4.5	Eli Lilly and Co.	9.0
Denmark	7.1	Other Net Assets (Liabilities)	1.0	Novo Nordisk AS, Class B	7.1
Exchange-Traded Fund(s)	4.5	Cash & Cash Equivalents	0.0	AstraZeneca PLC	6.2
Germany	3.0			Merck & Co., Inc.	6.0
Other Net Assets (Liabilities)	1.0			Zoetis Inc.	4.7
Cash & Cash Equivalents	0.0			SPDR S&P Biotech ETF	4.5
				Thermo Fisher Scientific Inc.	4.1
				AbbVie Inc.	3.7
				Intuitive Surgical Inc.	3.3
				Boston Scientific Corp.	3.1
				Stryker Corp.	3.1
				Siemens Healthineers AG	3.0
				Johnson & Johnson	3.0
				Danaher Corp.	2.9
				IQVIA Holdings Inc.	2.4
				GSK PLC	2.2
				Amgen Inc.	2.1
				CVS Health Corp.	2.0
				GE HealthCare Technologies Inc.	1.7
				Edwards Lifesciences Corp.	1.6
				Roche Holding AG	1.6
				McKesson Corp.	1.0
				Cigna Corp.	1.0
				Total Net Assets (in \$000's)	\$140,752

The summary of investment portfolio may change due to ongoing portfolio transactions of the Fund and updates are available on a quarterly basis.

The prospectus and other information about the fund are available on the internet at www.ci.com.

